Skip to main content
Top
Published in: Medical Oncology 2/2006

01-06-2006 | Original Article

Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC)

Authors: F. Yang, P. Shi, X. Xi, S. Yi, H. Li, Q. Sun, M. Sun

Published in: Medical Oncology | Issue 2/2006

Login to get access
Metadata
Title
Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC)
Authors
F. Yang
P. Shi
X. Xi
S. Yi
H. Li
Q. Sun
M. Sun
Publication date
01-06-2006
Publisher
Humana Press
Published in
Medical Oncology / Issue 2/2006
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:23:2:191

Other articles of this Issue 2/2006

Medical Oncology 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine